#USA #Las Vegas #VIVA Foundation #Vascular Medicine #VEINS 2026

Latest Advances in Venous Disease Treatments at VEINS 2026

The VEINS 2026 conference, held at the iconic Bellagio in Las Vegas, showcased the latest breakthroughs in vascular medicine, particularly in the management and treatment of venous diseases. Organized by the VIVA Foundation, a prominent non-profit organization dedicated to advancing education and research in vascular health, the conference revealed numerous late-breaking clinical trial results that have significant implications for patient care.

The VIVA Foundation aims to enhance vascular medicine through innovative research and education, focusing on the diagnosis, intervention, and management of venous disorders. This year’s conference featured comprehensive presentations on various clinical trials that spanned diverse topics related to venous health.

Highlights of Key Clinical Trials

1. Cyanoacrylate Closure in Patients with C6 Disease
Presented by Dr. Manj Gohel, this prospective study evaluated the effectiveness of cyanoacrylate closure (CAC) for patients suffering from chronic venous disease (CVD) at various stages, specifically targeting C6 disease, which is often severe. The findings over a 24-month period revealed an impressive ulcer healing rate of 88.1% and a recurrence rate of only 22.9%. Notably, the research indicates that CAC is both a durable and effective treatment option for patients with serious venous issues.

2. Interim Results of the BERG02 Study
This single-center study assessed a novel percutaneous device designed for the treatment of superficial and perforator vein incompetence. Led by Dr. Steve Elias, the preliminary analysis showcases a 100% technical success rate within the first six months, highlighting the promising safety and performance profile of this new device combined with sclerotherapy.

3. Real-World Registry of the Abre Venous Stent System
Presented by Dr. Paul Gagne, this investigation revealed favorable outcomes in treating central venous disease. With over 150 patients involved, results indicated no significant stent fractures and a low re-intervention rate within 30 days, marking the Abre stent as a compelling option for managing symptomatic iliofemoral venous obstruction.

4. RAPID-PE Study on Mechanical Thrombolysis for Pulmonary Embolism
Dr. Wissam A. Jaber presented the early results from this novel approach using a mechanically channeled thrombolysis device aimed at treating acute intermediate-risk pulmonary embolism (PE) without prolonged lytic infusion. Early results suggest this method is associated with low rates of serious adverse events, demonstrating its safety and potential efficacy.

5. C-TRACT Trial on Iliac Vein Stent Placement
Dr. Suresh Vedantham highlighted the long-term quality of life improvements in patients with post-thrombotic syndrome undergoing endovascular therapy. The results showed a significant enhancement in health-related quality of life metrics over 24 months, reinforcing the benefits of stenting in alleviating severe venous symptoms.

Impact on Patient Care

The results presented at VEINS 2026 are pivotal as they not only enhance the understanding of various treatment modalities but also emphasize the importance of individualized patient care strategies in vascular medicine. As vascular health continues to gain prominence in medical research and practice, conferences like VEINS serve as essential platforms for professionals to exchange knowledge, discuss emerging technologies, and improve patient outcomes through the adoption of innovative therapeutic options.

The VIVA Foundation remains committed to leading the charge in vascular medicine, advocating for ongoing research, and ensuring that healthcare practitioners have access to the latest evidence-based practices. For further information regarding the conference and the VIVA Foundation’s initiatives, please visit VIVA Foundation.

Through these enlightening discussions and groundbreaking trials, VEINS 2026 reiterates the evolving landscape of vascular medicine and its potential to significantly enhance patient experiences and outcomes.